Quantitative impact of changes in marrow cellularity, skeletal size, and bone mineral density on active marrow dosimetry based upon a reference model

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90

Background

Based on theoretical and preclinical results, terbium-161 may be a valid alternative to lutetium-177 and yttrium-90 in radionuclide therapies. The large low-energy electron emission from terbium-161 is a favorable feature in the treatment of disseminated disease, but its impact on the radiosensitive bone marrow needs to be evaluated. Using voxel-based skeletal dosimetry models in which active bone marrow is defined as regions containing stem cells and progenitor cells of the hematopoietic lineage, we generated S-values (absorbed dose per decay) for terbium-161 and evaluated its distribution-dependence in bone marrow cavities.

Methods

S-values in the active bone marrow were calculated for terbium-161, lutetium-177, and yttrium-90 irradiation using two (male/female) image-based bone marrow dosimetry models. The radionuclides were distributed to one of the three structures that define the spongiosa bone region in the skeletal models: (i) active bone marrow, (ii) inactive bone marrow, or (iii) surface or whole volume of the trabecular bone. Decay data from ICRP 107 were combined with specific absorbed fractions to calculate S-values for 13 skeletal sites. To increase the utility, the skeletal site-specific S-values were averaged to produce whole-body average S-values and spongiosa average S-values.

Results

For yttrium-90, the high-energy β particles irradiate the active marrow regardless of the source compartment, consistently generating the highest S-values (65–90% higher). Between terbium-161 and lutetium-177, the largest differences in S-values were with an active marrow source (50%), such as self-irradiation, due to the contribution of the short-ranged conversion and Auger electrons from terbium-161. Their influence decreased as the source moved to inactive marrow or the surface or volume of the trabecular bone, reducing the S-values and the differences between terbium-161 and lutetium-177 (15–35%).

Conclusion

The S-values of terbium-161 for active bone marrow and, consequently, the bone marrow toxicity profile were more dependent on the radionuclide distribution within the bone marrow cavity than the S-values of lutetium-177 and yttrium-90. This effect was attributed to the considerable low-energy electron emission of terbium-161. Therefore, it will be critical to investigate the bone marrow distribution of a particular radiopharmaceutical for accurate estimation of the active bone marrow dose.

Quantification of the volume fraction of fat, water and bone mineral in spongiosa for red marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/)CT

A patient-specific absorbed dose calculation for red marrow dosimetry requires quantifying patient-specific volume fractions of the red marrow, yellow marrow, and trabecular bone in the spongiosa of several skeletal sites. This quantification allows selecting appropriate S values calculated from the parameterized radiation transport models for bone and bone marrow dosimetry. Currently, no comprehensive, individualized, and non-invasive procedure is available for quantifying the volume fractions of red marrow, yellow marrow, and trabecular bone in the spongiosa. This study aims to provide a new quantitative method based on dual-energy computed tomography to fill this gap in red marrow dosimetry using a (SPECT/)CT system.

METHODS

First, a method for parametrizing the photon attenuation coefficients relative to water was implemented. Next, a method to calculate the effective atomic number (Z_eff) and effective mass density (ρ_eff) using dual-energy CT (DECT) was employed. Lastly, two- and three-material decomposition using a dual-energy quantitative CT method (DEQCT) was performed in an anthropomorphic spine phantom and two bone samples of a boar, respectively. The measurements of Z_eff and ρ_eff were compared with the syngo.CT DE Rho/Z tool (Siemens Healthineers). Furthermore, the DEQCT method implemented in this study (DEQCT-I) was compared with a second DEQCT method based on the use of external material standards (DEQCT-II). DEQCT-II was used as reference method for calculating relative errors.

RESULTS

The two-material decomposition in the anthropomorphic spine phantom presented a maximum relative error of -10% for the bone mineral density quantification. Furthermore, Z_eff and ρ_eff calculated by DEQCT-I differed from syngo.CT DE Rho/Z tool by less than 4.4% and 1.9%, respectively. The three-material decomposition in the two bone samples showed a maximum relative error of 21%, -17%, and 15% for the quantification of the volume fractions of fat, water, and bone mineral equivalent materials. Lastly, Z_eff and ρ_eff calculated by DEQCT-I differed from syngo.CT DE Rho/Z tool by less than 8.2% and 7.0%, respectively.

CONCLUSION

This study shows that quantifying the volume fraction of fat, water, and bone mineral using a phantom-independent and post-reconstruction DEQCT method is feasible. DEQCT-I has the advantage of not requiring prior information about the X-ray spectra or the detector sensitivity function, as is the case with spectral-based DEQCT methods. Instead, DEQCT-I, similar to other DEQCT methods depends on the chemical description of reference materials and a beam hardening correction function. DEQCT-I method provides an individualized and non-invasive procedure using a (SPECT/)CT system to apply S values based on the patient-specific volume fractions of yellow marrow, red marrow, and bone mineral in red marrow dosimetry.

Comparison of Voxel S-Value Methods for Personalized Voxel-based Dosimetry of 177 Lu-DOTATATE

PURPOSE

Voxel-based dosimetry is potentially accurate than organ-based dosimetry because it considers the anatomical variations in each individual and the heterogeneous radioactivity distribution in each organ. Here, voxel-based dosimetry for ¹⁷⁷ Lu-DOTATATE therapy was performed using single and multiple voxel S-value (VSV) methods and compared with Monte Carlo simulations. To verify these methods, we adopted sequential ¹⁷⁷ Lu-DOTATATE SPECT/CT dataset acquired from Sunway Medical Centre using the major vendor's SPECT/CT scanner (Siemens) METHODS: The administered activity of ¹⁷⁷ Lu-DOTATATE was 7.99 ± 0.36 GBq. SPECT/CT images were acquired 0.5, 4, 24, and 48 h after injection in Sunway Medical Centre. For the multiple VSV method VSV kernels of ¹⁷⁷ Lu in media with various densities were generated by GATE simulation first. The second step involved the convolution of the time-integrated activity map with each kernel to produce medium-specific dose maps. Third, each medium-specific dose map was masked using binary medium masks, which were generated from CT-based density maps. Finally, all masked dose maps were summed to generate the final dose map. VSV methods with four different VSV sets (1, 4, 10, and 20 VSVs) were compared. Voxel-wise density correction for the single VSV method was also performed. The absorbed doses in the kidneys, bone marrow, and tumors were analyzed, and the relative errors between the VSV and Monte Carlo simulation approaches were estimated. Organ-based dosimetry using OLINDA/EXM was also compared RESULTS: The accuracy of the multiple VSV approach increased with the number of dose kernels. The average dose estimation errors of a single VSV with density correction and 20 VSVs were less than 6% in most cases, although organ-based dosimetry using OLINDA/EXM yielded an error of up to 123%. The advantages of the single VSV method with density correction and the 20 VSVs over organ-based dosimetry were most evident in bone marrow and bone-metastatic tumors with heterogeneous medium properties.

CONCLUSION

The single VSV method with density correction and multiple VSV method with 20 dose kernels enabled fast and accurate radiation dose estimation. Accordingly, voxel-based dosimetry methods can be useful for managing administration activity and for investigating tumor dose responses to further increase the therapeutic efficacy of ¹⁷⁷ Lu-DOTATATE. This article is protected by copyright. All rights reserved.

Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box

Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel treatment modality that delivers highly potent alpha-particles to cancer cells or their environment. We review the advantages and challenges of imaging and dosimetry in implementing αRPT for cancer patients.

A cell-based dosimetry model for radium-223 dichloride therapy using bone micro-CT images and GATE simulations

Dosimetry at the cellular level has outperformed macrodosimetry in terms of agreement with toxicity effects in clinical studies. This fact has encouraged dosimetry studies aiming to quantify the absorbed doses needed to reach radiotoxicity at the cellular level and to inform recommendations on the administration of radium-223. The aim of this work is to qualitatively and quantitatively evaluate the absorbed doses of radium-223 and the interactions of the doses at the cellular level. The analysis was performed by Monte Carlo simulations in GATE using micro-CT image of a mouse. Two physics lists available in the GATE code were tested. The influence of single and multiple scattering models on the absorbed dose distribution and number of particle hits was also studied. In addition, the fuzzy c-means clustering method was used for data segmentation. The segmentation method was suitable for these analyses, particularly given that it was unsupervised. There was no significant difference in the estimated absorbed dose between the two proposed physics lists. The absorbed dose values were not significantly influenced by scattering, although single scattering resulted in twice as many interactions as multiple scattering. The absorbed dose histogram at the voxel level shows heterogeneous absorbed dose values within each shell, but the observations from the graph of the medians were comparable to those in the literature. The interaction histogram indicates 10⁴ events, although some voxels had no interactions with alpha particles. However, the voxels did not show absorbed doses capable of deterministic effects in the deepest part of the bone marrow. The absorbed dose distribution in images of mouse trabecular bone was compatible with simple geometric models, with absorbed doses capable of deterministic effects near the bone surface. The interaction distributions need to be correlated with in vivo studies for better interpretation.

Quantification of the trabecular bone volume fraction for bone marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT/)CT

A complete characterization of spongiosa (bone marrow plus trabecular bone) is required to calculate the absorbed dose to active bone marrow. Due to the complex microanatomy, it is necessary to apply non-conventional imaging methods in nuclear medicine. The aim of this study is validating a phantomless quantification method using dual-energy quantitative computed tomography (DEQCT) for the quantification of trabecular bone volume fraction for bone marrow dosimetry in molecular radiotherapy. First, a phantomless quantification method (mass fraction method) based on x-ray beam and detector sensitivity was validated in an integrated dual energy SPECT/CT and in a dual source computed tomography (DSCT) system for comparison. The validation was performed in a phantom consisting of different water, fat and hydroxyapatite compositions. Moreover, the European spine phantom (ESP) was used to simulate the spine geometry. Bone mineral content (BMC) of the whole vertebra and bone mineral density (BMD) in the spongiosa region of each phantom vertebra were measured using DEQCT and dual energy x-ray absorptiometry (DEXA). Lastly, BMC was measured in a patient using DEQCT and DEXA. Measured values of hydroxyapatite fraction and nominal values in the homemade phantom showed a good correlation. The relative error remained below 14.2%. Quantification of BMC (in whole vertebra) and BMD (in spongiosa) in the ESP showed a good agreement between measured values and nominal values. The relative error remained between 0.7% and 7.5% for BMC_SPECT/CT, 1.1% and 7.7% for BMC_DSCT, 5.4% and 32.0 for BMD_SPECT/CT, and 59.4% and 10.0% for BMD_DSCT. Quantification of BMC in lumbar vertebrae 1 and 2 of a patient showed relative errors of 7.6% and -8.4% between DEXA and DSCT. Our study shows that DEQCT using a mass fraction method (phantomless) enables quantification of hydroxyapatite in a clinical nuclear medicine setting. An overestimation of the hydroxyapatite volume fraction was observed in all quantified regions, in particular in the spongiosa region of ESP. This result might be related to insufficient information about the x-ray spectra and the detector sensitivity function.